Revenue: As of FY2025 Q1, the actual value is USD 5.004 M.EPS: As of FY2025 Q1, the actual value is USD -2.26.<h3>Segment Revenue</h3><ul><li>ZTlido: Net revenue for the three months ended March 31, 2025 was $3,986 thousand, a decrease from $10,278 thousand for the same period in 2024.</li><li>ELYXYB: Net revenue for the three months ended March 31, 2025 was $840 thousand, an increase from $606 thousand for the same period in 2024.</li><li>GLOPERBA: Net revenue for the three months ended March 31, 2025 was $178 thousand, with no revenue reported for the same period in 2024.</li></ul><h3>Operational Metrics</h3><ul><li>Loss from Operations: Loss from operations for the three months ended March 31, 2025 was -$27,898 thousand, compared to -$19,478 thousand for the same period in 2024.</li><li>Net Loss: Net loss for the three months ended March 31, 2025 was -$26,080 thousand, compared to -$24,377 thousand for the same period in 2024.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Proceeds from Operating Activities: Net cash proceeds from operating activities for the three months ended March 31, 2025 were $6,007 thousand, compared to $9,391 thousand for the same period in 2024.</li><li>Net Cash Used for Investing Activities: Net cash used for investing activities for the three months ended March 31, 2025 was -$395 thousand, compared to -$150 thousand for the same period in 2024.</li><li>Net Cash Used for Financing Activities: Net cash used for financing activities for the three months ended March 31, 2025 was -$3,084 thousand, compared to -$11,196 thousand for the same period in 2024.</li></ul><h3>Unique Metrics</h3><ul><li>Derivative Liabilities: Gain on derivative liability for the three months ended March 31, 2025 was $10,409 thousand, compared to a loss of $457 thousand for the same period in 2024.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company plans to continue investing in sales and marketing to broaden awareness of ZTlido, GLOPERBA, and ELYXYB, and in research and development to advance product candidates SEMDEXA, SP-103, and SP-104.</li><li>Non-Core Business: The company formed a joint venture, Scilex Bio, Inc., to develop and commercialize a next-generation reversible MAO-B Inhibitor for the treatment of obesity and neurodegenerative diseases.</li></ul>

Scilex - CW27 | 10-Q: FY2025 Q1 Revenue: USD 5.004 M